Business Wire

Mano Būstas Partners with Airship to Power Proactive, Anticipatory Communications with Customers

21.1.2021 11:00:00 EET | Business Wire | Press release

Share

Customer engagement company Airship and City Service, one of the largest corporate groups engaged in facility and property management and integrated utility services in Europe, today unveiled a new partnership that will streamline communications between its Lithuanian property management company, Mano Būstas and its hundreds of customers across the region. Beginning in January, Airship’s Customer Engagement Platform will enable Mano Būstas to automate communication with customers across in-app messaging, push notifications, email, and SMS, offering a better customer service experience by proactively answering common questions throughout all stages of the customer lifecycle. City Service is offering the new services to Mano Būstas clients at a first stage, with plans to roll out the cooperation to other businesses and countries later in the year.

This collaboration is part of City Service’s strategic direction towards digitalising and automating their full business processes in order to better serve customers online in a quicker and more efficient manner. By automating customer communications via mobile, Mano Būstas estimates a reduction in customer inbound calls to its customer service centre by more than 30%. “Based on our years of service, we have created an extensive list of frequently asked questions at different stages in the customer lifecycle, so now, thanks to Airship, we will be able to send the answers to their questions on a timely manner before they contact us,” said Mindaugas Genys, Head of Mano Būstas. “We expect this will significantly reduce the time our customer service spends on reactive communication, that can otherwise be spent by delivering a proactive contact, checking-in with customers to ensure everything is okay and whether they need additional services from us”.

Through Airship’s technology, Mano Būstas will also get clear visibility into customers that engage with messages and the actions they take, which will provide deeper insights into customers’ preferences. With this information, Mano Būstas will be able to segment their database into smaller data sets to be able to create even more targeted automations in the future.

“Industries in every region across the globe are recognising that engaging customers on mobile is key to providing next-level service for stronger and more valuable customer relationships," said Patrick Mareuill, Managing Director EMEA at Airship. "We are happy to welcome Mano Būstas on board Airship to more quickly realise these goals and generate immediate business value."

About Mano Būstas: Mano Būstas provides administration services for apartment buildings in Vilnius, Kaunas, Klaipėda, Palanga, Neringa, Šiauliai, Radviliškis, Alytus, Šilutė, Šilalė, Panevėžys, Šakiai, Pasvalys, Tauragė, Biržai and Birštonas, with more than 180 thousand households using the company's services in Lithuania.

About City Service: City Service is a holding company which manages one of the largest corporate groups engaged in facility and property management and integrated utility services in Lithuania, Latvia, Poland, Spain and St. Peterburg. The shares of the company is listed on the Warshaw stock exchange.

About Airship

Thousands of the world’s leading brands rely on Airship to spark closer connections with their customers through highly contextual and relevant interactions. Only Airship’s Customer Engagement Platform takes a mobile-first, data-led approach that enables brands to focus on individuals and their needs, not which marketing channels to use. Airship makes it much simpler and more effective to grow customer lifetime value in the omnichannel era.

With trillions of interactions intelligently orchestrated across mobile apps, mobile wallet, SMS, websites, and email, Airship optimizes the entire customer journey across all digital touchpoints at scale.

For more information, visit www.airship.com, read our blog or follow us on Twitter, LinkedIn and Facebook.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

North America:
Danielle Stickler
Mission North for Airship
+1 415-749-9124
airship@missionnorth.com

Corey Gault
Airship
+1 503-206-9164
corey@airship.com

UK:
Ana Williams
Airship
+44 (0)20 3405 5160
Ana.Williams@airship.com

City Service PR representative
Paulius Ugianskis
+37065653952

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Yubico Appoints Poupak Modirassari Enbom as Chief Marketing Officer to Accelerate Global Momentum and Drive Market Leadership30.3.2026 16:00:00 EEST | Press release

Yubico (NASDAQ STOCKHOLM: YUBICO), the creator of the most secure passkeys and a leading provider of hardware authentication security keys, today announced the appointment of Poupak Enbom as Chief Marketing Officer (CMO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330278027/en/ Enbom joins Yubico at a pivotal moment as organizations worldwide accelerate the shift to phishing-resistant authentication and modern identity security in the age of AI. “We’re excited to welcome Poupak to Yubico,” said Jerrod Chong, acting chief executive officer, Yubico. “As the threat landscape evolves with AI-driven attacks and increasing automation, organizations are rethinking how they secure digital identities of both humans and AI agents at scale. She brings a unique combination of technical depth, global leadership, and customer-first mindset that will help us continue to expand our impact and support our customers and partners around

HistoSonics Treats First Patients Evaluating the Edison® Histotripsy System for the Treatment of Benign Prostatic Hyperplasia (BPH)30.3.2026 15:00:00 EEST | Press release

HistoSonics, the developer of the Edison® Histotripsy System and novel histotripsy therapy platform, today announced the successful treatments of the first patients in WOLVERINE, a prospective feasibility trial evaluating the Edison® Histotripsy System for the treatment of benign prostatic hyperplasia (BPH) at Prince of Wales Hospital in Hong Kong, a teaching hospital for The Chinese University of Hong Kong. The Edison System is a novel, non-invasive, image guided platform that uses the mechanical properties of focused ultrasound, called histotripsy, to destroy unwanted tissue without the need for invasive procedures, and with potentially fewer side effects than traditional, invasive therapies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330349844/en/ HistoSonics Non-Invasive Edison Histotripsy System. Image credit: HistoSonics WOLVERINE is a prospective, multi-center, single-arm feasibility trial designed to evaluate

Westinghouse Celebrates Record-breaking 80 Years of Nuclear Fuel Manufacture at Springfields30.3.2026 15:00:00 EEST | Press release

The Westinghouse Springfields facility in Lancashire, UK, has marked a significant milestone as the oldest continuous nuclear fuel manufacturing site in the world, starting from its original license on the 28th, March 1946. The site was chosen by the UK Government to develop nuclear fuel for the world’s earliest civil nuclear power stations, as well as subsequent Magnox and Advanced Gas Reactors (AGR) reactors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330135973/en/ From left to right: Sophie Lemaire; Marc Chevrel; Rory O'Neill; Craig Boothby; and Robert Gofton, CEO at Nuclear Institute Across the last eight decades, the Springfields site has supported the UK nuclear fleet, manufacturing more than eight million AGR pins, sintering and pressing over 500 million AGR uranium pellets and 222,000 AGR grids – which is equivalent to burning over 685 tonnes of coal, avoiding the emission of nearly 3 billion tonnes of CO2. Sp

Biocytogen Grants Taisho Pharmaceutical a License to its RenNano ® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 14:00:00 EEST | Press release

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro

Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 14:00:00 EEST | Press release

Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye